HERU WANG: Open Payments
NPI 1124857768 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$568 in 18 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $692 · 2025 $568
Food & beverage: $568
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 3 | $137 |
| Gilead Sciences, Inc. | 1 | $109 |
| Amgen Inc. | 2 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Merck Sharp & Dohme LLC | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Viatris Specialty LLC | 1 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $28 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| SANOFI PASTEUR INC. | 1 | $19 |
Products named: MOUNJARO, Vemlidy, TAVNEOS, GVOKE HYPOPEN, ROTATEQ, REXULTI, YUPELRI, OFEV.
Industry payments across CA — which companies pay providers there.
